Number needed to treat associated with ixekizumab and etanercept from UNCOVER-2 and UNCOVER-3 Phase III trials in the treatment of moderate-to-severe psoriasis

被引：0
|
作者：
Foster, S. [1 ]
Zhu, B. [1 ]
Burge, R. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 05期
关键词：
D O I：
10.1016/j.jid.2016.02.177
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
150
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [31] A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER 3
    Griffiths, Christopher E.
    Reich, Kristian
    Lebwohl, Mark
    Van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Carlier, Hilde
    Cameron, Gregory
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta
    Ball, Susan
    Braun, Daniel
    Osuntokun, Olawale
    Heffernan, Michael
    Nickoloff, Brian
    Papp, Kim
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S17 - S17
  • [32] Evaluation of the Psoriasis Skin Appearance and Bothersomeness (PSAB) measure in patients with moderate to severe psoriasis treated with ixekizumab compared to etanercept and placebo: Results from UNCOVER-2
    Luger, Thomas
    Gottlieb, Alice
    Puig, Lluis
    Nikai, Enkeleida
    Zhu, Baojin
    Heredia, Emily Edson
    Lin, Chen Yen
    Goldblum, Orin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB250 - AB250
  • [33] Time course of ixekizumab drug levels and the relationship at week 60 to efficacy in patients with moderate-to-severe plaque psoriasis (UNCOVER-3)
    Reich, K.
    Choi, S. L.
    Jackson, K.
    Mallbris, L.
    Blauvelt, A.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 : 39 - 39
  • [34] Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Sub-analysis of the Phase 3 UNCOVER trials in patients with baseline PASI > 15
    Spelman, L.
    Rubel, D.
    Brnabic, A.
    Burkhardt, N.
    Kelin, K.
    Gurbuz, S.
    Foley, P.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 40 - 41
  • [35] Ixekizumab (IXE) treatment enables rapid improvements in health-related quality of life (HRQoL) and itch: Results from UNCOVER-2 and UNCOVER-3
    Burkhardt, N.
    Blauvelt, A.
    Leonardi, C.
    Sofen, H.
    Burge, R.
    Zhu, B.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 44 - 44
  • [36] Maintenance of Efficacy Results from UNCOVER-1: A Phase 3 Trial of Ixekizumab for Moderate-to-Severe Plaque Psoriasis
    Leonardi, C.
    Leutz, A.
    Blauvelt, A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Cameron, G. S.
    Erickson, J.
    Zhao, F.
    Shrom, D. S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Gordon, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
  • [37] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
    Leonardi, Craig
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Zhao, Fangyi
    Shrorn, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Gordon, Kenneth
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
  • [38] Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study (UNCOVER-1)
    Gordon, Kenneth
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel K.
    Erickson, Janelle
    Zhao, Fangyi
    Shrom, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Leonardi, Craig
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S6 - S6
  • [39] Efficacy and safety of ixekizumab compared to etanercept or placebo treatment of patients with moderate-to-severe plaque psoriasis and palmoplantar involvement over a 60-week dosing period: results from UNCOVER-3, a Phase 3 trial
    Warren, R. B.
    Morita, A.
    Menter, A.
    Duffin, K. Callis
    Langley, R.
    Amato, D.
    Dennehy, E. B.
    Kerr, L. N.
    Shrom, D.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 78 - 79
  • [40] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Gordon, K. B.
    Blauvelt, A.
    Papp, K. A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Reich, K.
    Amato, D.
    Ball, S. G.
    Braun, D. K.
    Cameron, G. S.
    Erickson, J.
    Konrad, R. J.
    Muram, T. M.
    Nickoloff, B. J.
    Osuntokun, O. O.
    Secrest, R. J.
    Zhao, F.
    Mallbris, L.
    Leonardi, C. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 345 - 356
12345